Navigation Links
Tailoring glioblastoma therapies: 1 size does not fit all
Date:2/6/2008

An upcoming G&D paper from Dr. Azad Bonni and colleagues at Harvard Medical School lends new insight into how the unique genetic signature of glioblastoma tumors affects treatment efficacy - a finding with promising hope for the therapeutic targeting of the leading cause of cancer-related deaths in the young and middle-aged population.

Dr. Bonni's group found that the transcription factor STAT3 has either a tumor promoting or tumor suppressive effect depending upon the genetic profile of the glioblastoma tumor.

Glioblastomas are the most common and aggressive type of adult brain cancer, with an annual incidence of approximately 13,000 in the United States, and an expected median survival rate of just over a year. STAT3 is a cytokine-activated transcription factor that has been previously reported to play a pro-oncogenic role in tumor development. Thus, much effort has been aimed at the development of STAT3 inhibitors as chemotherapeutic agents.

Dr. Bonni and colleagues now report that STAT3 can function as either a tumor suppressor or an oncoprotein. Using a mouse model system of two common genetic mutations in glioblastomas - PTEN deficiency or EGFRvIII activation -- the researchers show that PTEN regulates STAT3 tumor suppressor function, while STAT3 cooperates with the EGFRvIII oncoprotein to promote tumor growth.

Thus, the researchers convincingly demonstrate a need for effective therapies tailored to the unique genetic thumbprint of individual glioblastoma tumors. "These findings may change the way we approach not only glioblastoma but other types of cancer as well", says Azad Bonni, senior author of the study.


'/>"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1

Related medicine news :

1. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
2. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... MALO, FRANCE (PRWEB) , ... January 22, 2017 , ... ... Indian Ocean, isolated from the rest of the world with ZANZIBAR MILKY CREAM. Inspired ... Phytocéane used key ingredients like Virgin Coconut Oil and moisturizing vegetal coral to create ...
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a company that ... product to the United States as part of its presence to expand its market ... aims to reduce the productions of nasty toxins as a result of drinking alcohol, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates ... joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient ... to add this excellent dermatology practice to our group’s medical services,” explains NCMA ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... A new ... donate items they no longer use or need, from clothes to couches to dressers ... unwanted items and take them to the nearest Goodwill donation center through February 28th. ...
(Date:1/20/2017)... ... ... Lice Troopers, the lice removal company based in South Florida, has seen a ... , “It happens every year around this time,” says owner, Arie Harel. “Many ... the head-to-head gateway that lice need to spread.” , As children return to classrooms ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 2017 Research and Markets has announced ... By Type of Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By ... Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast to 2022" ... ... services, market segments, especially clinical lab testing, which has evolved ...
(Date:1/21/2017)... 2017 ARMO BioSciences, Inc., a late-stage immuno-oncology ... Company,s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) at ... Society of Clinical Oncology (ASCO), taking place January 19-21, ... "AM0010 induces the expansion of novel ... cells in the blood and tumors of our patients," ...
(Date:1/21/2017)...  Faruqi & Faruqi, LLP, a leading national securities law ... (NASDAQ: KMPH ) of the federal securities class ... directors and underwriters of the Company,s April 16, 2015 Initial ... plaintiff. The lawsuit has been filed in the ... Johnson County on behalf of all those who ...
Breaking Medicine Technology: